NCT00761540View on ClinicalTrials.gov

To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
DiabetesHealthy
Interventions
DRUG

liraglutide

Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)

DRUG

placebo

Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)

DRUG

liraglutide

Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)

DRUG

placebo

Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)

DRUG

liraglutide

Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)

DRUG

placebo

Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)

Trial Locations (1)

100032

Novo Nordisk Investigational Site, Beijing

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00761540 - To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo | Biotech Hunter | Biotech Hunter